Message from President

Our hearts and prayers go out to those who lost their lives or have otherwise suffered due to the Great East Japan Earthquake.
Beginning immediately after the earthquake, the Eisai Group has worked to confirm and secure the safety of our employees. We united as a company to promptly begin activities such as providing relief supplies to patients and medical institutions in the affected areas, and making monetary donations to organizations that are providing support on the frontlines of those areas. In the future also, we intend to continue to make utmost efforts to support the patients affected by the disaster, their families, and the wider public, as well as our commitment to ensuring preparations are in place for the stable supply of pharmaceuticals when emergencies occur, in accordance with our corporate mission as described in our Articles of Incorporation. We pray for the earliest possible recovery of the areas affected by the earthquake and ensuing tsunami.

Haruo Naito
President and CEO

The worldwide pharmaceuticals market is moving into an era of great globalization, amidst sluggish growth caused by increasingly harsh conditions in matured markets and expanding opportunities for growth in emerging markets. As a Group, we plan to enter all of the world's 20 largest pharmaceutical markets, which includes the recent additions of Russia, Brazil, Mexico, Turkey, etc., and increase the number of countries in which Eisai products are available, thereby contributing further to patients. During the past fiscal year, the Eisai Group experienced the expiration of the Aricept patent in the United States. At the same time however, we were able to make a great achievement in the field of oncology, one of our defined areas of therapeutic focus in which high unmet medical needs exist. We successfully launched Halaven, the first anticancer agent to be discovered and developed in-house, in the United States and Europe, while also obtaining approval in Japan. In addition, this year we launched our new 5-year mid-term strategic plan “HAYABUSA” with the aim of ensuring future growth of Halaven and other products in the field of oncology, and contributing to an ever-greater number of patients in newly developing nations and around the world.
The Eisai Group is determined to work vigorously to achieve the plan “HAYABUSA” in an effort to continuously improve corporate value, in accordance with our corporate mission. We ask all of you for continued support going forward.

May, 2011